The Evolving Strategy of Californium-252 Neutron Intracavitary Brachytherapy in Treating Patients With Low-Lying T2 or T3 Rectal Adenocarcinoma: From Fixed to Individualized Regime With Intrarectal Peritumoral Injection of Amifostine.
252Cf neutron
brachytherapy
radiotherapy
rectal adenocarcinoma
sphincter preservation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
08
2021
accepted:
13
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
To retrospectively and comparatively evaluate the improvement of the efficacy and safety on the addition of Phase I: from 2009 to 2011, 157 patients were treated with additional The 4-year local control rates for the entire T2 and T3 patients were 69.4, 72.0, and 79.3%, while the 4-year overall survival rates were 63.1, 54.7, and 72.0% (P=0.08), and the 4-year disease-free survival rates were 55.4, 52.0, and 69.5% (P=0.053) in Phases I, II, and III, respectively. The late complication (LAC, ≥G2) rates were 33.8, 26.7, and 15.9%, respectively (P=0.012), and the serious LAC (≥G3) rates were 4.5, 4.2, and 0%, respectively, in Phases I, II, and III. Concurrent chemo-EBRT combined with individualized
Identifiants
pubmed: 34868971
doi: 10.3389/fonc.2021.758698
pmc: PMC8636320
doi:
Types de publication
Journal Article
Langues
eng
Pagination
758698Informations de copyright
Copyright © 2021 Xiong, Shao, Liu, Zhou, Li, Liao, Zhang, Dai, Li and Lei.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):110-8
pubmed: 25015203
Ann Oncol. 2018 Jul 1;29(7):1521-1527
pubmed: 29718095
Clin Oncol (R Coll Radiol). 2007 Nov;19(9):701-5
pubmed: 17714925
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
J Clin Oncol. 2012 Nov 1;30(31):3827-33
pubmed: 23008301
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Lancet Oncol. 2008 May;9(5):494-501
pubmed: 18452860
Ann Surg Oncol. 2017 Jul;24(7):1904-1915
pubmed: 28324284
J Clin Oncol. 2011 Dec 10;29(35):4633-40
pubmed: 22067400
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513
pubmed: 28479372
Eur J Cancer. 1974 Apr;10(4):203-5
pubmed: 4216457
J Gastrointest Oncol. 2014 Jun;5(3):212-7
pubmed: 24982769
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):822-8
pubmed: 24495589
Sci Rep. 2017 Jan 17;7:40619
pubmed: 28094790
Colorectal Dis. 2010 Aug;12 Suppl 2:30-6
pubmed: 20618365
J Surg Res. 2018 Jun;226:15-23
pubmed: 29661280
Lancet Oncol. 2003 Mar;4(3):158-66
pubmed: 12623361
Dis Colon Rectum. 2007 Dec;50(12):2032-9
pubmed: 17896138
Curr Colorectal Cancer Rep. 2017 Feb;13(1):61-72
pubmed: 29445322
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):198-204
pubmed: 27726909